HER2扩增在转移性结直肠癌中的研究进展

摘要/Abstract

摘要：

多项研究表明,人表皮生长因子受体2(HER2)扩增可能是RAS野生型转移性结直肠癌(mCRC)患者抗表皮生长因子受体单克隆抗体靶向耐药的预测性生物标志物。HER2双重抑制剂曲妥珠单抗联合拉帕替尼或帕妥珠单抗初步显示出对RAS野生型mCRC患者良好的抗肿瘤效果。HER2靶向治疗策略有可能改变mCRC患者临床相关亚群的治疗模式。

关键词:结直肠肿瘤,基因, erbB-2,生物标记,分子靶向治疗

Abstract:

Several studies have shown that human epidermal growth factor receptor 2 (HER2) amplification could be a predictive biomarker of resistance to anti-epidermal growth factor receptor monoclonal antibodies in patients with RAS wild-type metastatic colorectal cancer (mCRC). Dual HER2 inhibition with trastuzumab plus lapatinib or pertuzumab has shown promising preliminary anti-tumoral efficacy in RAS wild-type mCRC. HER2-targeted therapeutic strategies have the potential to change the treatment paradigm for a clinically relevant subgroup of patients with mCRC.

Key words:Colorectal neoplasms,Genes, erbB-2,Biomarkers,Molecular targeted therapy

于姣姣, 王军, 王利康, 姚南. HER2扩增在转移性结直肠癌中的研究进展[J]. 国际肿瘤学杂志, 2021, 48(4): 246-249.

Yu Jiaojiao, Wang Jun, Wang Likang, Yao Nan. Advances in the amplification of HER2 in metastatic colorectal cancer[J]. Journal of International Oncology, 2021, 48(4): 246-249.

参考文献24

[1]	Martini G, Troiani T, Cardone C, et al. Present and future of metastatic colorectal cancer treatment: a review of new candidate targets[J]. World J Gastroenterol, 2017, 23(26):4675-4688. DOI: 10.3748/wjg.v23.i26.4675. doi:10.3748/wjg.v23.i26.4675
[2]	Li ZN, Zhao L, Yu LF, et al. BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy[J]. Gastroenterol Rep (Oxf), 2020, 8(3):192-205. DOI: 10.1093/gastro/goaa022.
[3]	Li QH, Wang YZ, Tu J, et al. Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance[J]. Gastroenterol Rep (Oxf), 2020, 8(3):179-191. DOI: 10.1093/gastro/goaa026.
[4]	苏昊, 刘文杰, 包满都拉, 等. 转移性结直肠癌西妥昔单抗耐药的分子机制[J]. 国际肿瘤学杂志, 2020, 47(5):308-311. DOI: 10.3760/cma.j.cn371439-20200208-00025.
[5]	Sforza V, Martinelli E, Ciardiello F, et al. Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colo-rectal cancer[J]. World J Gastroenterol, 2016, 22(28):6345-6361. DOI: 10.3748/wjg.v22.i28.6345. doi:10.3748/wjg.v22.i28.6345
[6]	Siena S, Sartore-Bianchi A, Marsoni S, et al. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer[J]. Ann Oncol, 2018, 29(5):1108-1119. DOI: 10.1093/annonc/mdy100. doi:10.1093/annonc/mdy100
[7]	Gutierrez C, Schiff R. HER2: biology, detection, and clinical implications[J]. Arch Pathol Lab Med, 2011, 135(1):55-62. DOI: 10.1043/2010-0454-rar.1. doi:10.5858/2010-0454-RAR.1
[8]	Liu F, Ren C, Jin Y, et al. Assessment of two different HER2 scoring systems and clinical relevance for colorectal cancer[J]. Virchows Arch, 2020, 476(3):391-398. DOI: 10.1007/s00428-019-02668-9. doi:10.1007/s00428-019-02668-9
[9]	Shimada Y, Yagi R, Kameyama H, et al. Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer[J]. Hum Pathol, 2017, 66:1-9. DOI: 10.1016/j.humpath.2017.02.004. doi:10.1016/j.humpath.2017.02.004
[10]	Fujii S, Magliocco AM, Kim J, et al. International harmonization of provisional diagnostic criteria for ERBB2-amplified metastatic colo-rectal cancer allowing for screening by next-generation sequencing panel[J]. JCO Precis Oncol, 2020, 4:6-19. DOI: 10.1200/PO.19.00154.
[11]	Siravegna G, Sartore-Bianchi A, Nagy RJ, et al. Plasma HER2 (ERBB2) copy number predicts response to HER2-targeted therapy in metastatic colorectal cancer[J]. Clin Cancer Res, 2019, 25(10):3046-3053. DOI: 10.1158/1078-0432.CCR-18-3389. doi:10.1158/1078-0432.CCR-18-3389pmid:30808777
[12]	Valtorta E, Martino C, Sartore-Bianchi A, et al. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study[J]. Mod Pathol, 2015, 28(11):1481-1491. DOI: 10.1038/modpathol.2015.98. doi:10.1038/modpathol.2015.98
[13]	Belli V, Matrone N, Napolitano S, et al. Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models[J]. J Exp Clin Cancer Res, 2019, 38(1):236. DOI: 10.1186/s13046-019-1230-z. doi:10.1186/s13046-019-1230-z
[14]	Bertotti A, Migliardi G, Galimi F, et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colo-rectal cancer[J]. Cancer Discov, 2011, 1(6):508-523. DOI: 10.1158/2159-8290.CD-11-0109. doi:10.1158/2159-8290.CD-11-0109pmid:22586653
[15]	Jeong JH, Kim J, Hong YS, et al. HER2 amplification and cetu-ximab efficacy in patients with metastatic colorectal cancer harboring wild-type RAS and BRAF[J]. Clin Colorectal Cancer, 2017, 16(3): e147-e152. DOI: 10.1016/j.clcc.2017.01.005.
[16]	Sartore-Bianchi A, Amatu A, Porcu L, et al. HER2 positivity predicts unresponsiveness to EGFR-targeted treatment in metastatic colorectal cancer[J]. Oncologist, 2019, 24(10):1395-1402. DOI: 10.1634/theoncologist.2018-0785. doi:10.1634/theoncologist.2018-0785pmid:30952821
[17]	Raghav K, Loree JM, Morris JS, et al. Validation of HER2 amplification as a predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer[J]. JCO Precis Oncol, 2019, 3(3):1-13. DOI: 10.1200/PO.18.00226.
[18]	Mezni E, Vicier C, Guerin M, et al. New therapeutics in HER2-positive advanced breast cancer: towards a change in clinical practices? pi[J]. Cancers (Basel), 2020, 12(6): 1573. DOI: 10.3390/cancers12061573.
[19]	Siena S, Sartore-Bianchi A, Trusolino L, et al. Abstract CT005: final results of the HERACLES trial in HER2-amplified colorectal cancer[J]. Cancer Res, 2017, 77 (Supple 13):CT005. DOI: 10.1158/1538-7445.AM2017-CT005.
[20]	Meric-Bernstam F, Hurwitz H, Raghav KPS, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study[J]. Lancet Oncol, 2019, 20(4):518-530. DOI: 10.1016/S1470-2045(18)30904-5. doi:10.1016/S1470-2045(18)30904-5
[21]	Nakamura Y, Okamoto W, Kato T, et al. 526PD-TRIUMPH: primary efficacy of a phase Ⅱ trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): a GOZILA sub-study[J]. Ann Oncol, 2019, 30(Suppl 5):v199-v200. DOI: 10.1093/annonc/mdz246.004.
[22]	Strickler JH, Zemla T, Ou FS, et al. 527PD-Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): initial results from the MOUNTAINEER trial[J]. Ann Oncol, 2019, 30 (Supple 5):v200. DOI: 10.1093/annonc/mdz246.005.
[23]	Martinelli E, Troiani T, Sforza V, et al. Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-a-mplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case[J]. ESMO Open, 2018, 3(1):e000299. DOI: 10.1136/esmoopen-2017-000299. doi:10.1136/esmoopen-2017-000299
[24]	陈功. 2019年结直肠癌治疗进展盘点[J]. 肿瘤综合治疗电子杂志, 2020, 1(6):89-90. DOI: 10.12151/JMCM.2020.01-10.